Pharmaceutical

Madrigal seeks expedited approval for NASH treatment

Madrigal Pharmaceuticals has commenced a rolling submission of an NDA seeking expedited approval from the US FDA for resmetirom.

Jul 3, 2023 - 20:00
Madrigal seeks expedited approval for NASH treatment
Madrigal Pharmaceuticals has commenced a rolling submission of an NDA seeking expedited approval from the US FDA for resmetirom.
Read the original article

Tags:

Previous Article

Chinese NMPA approves Innovent and IASO Bio’s myeloma therapy

Next Article

Chime Biologics, Leads and Beigene enter antibody development deal

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA’s Califf wants to get the public as excited about life expectancy as cures

STAT+: FDA’s Califf wants to get the public as excited ...

Nov 9, 2023

SBTi approves Piramal Pharma’s GHG reduction targets

SBTi approves Piramal Pharma’s GHG reduction targets

Sep 18, 2024

ITM raises $273 million to fund radionuclide therapy pipeline

ITM raises $273 million to fund radionuclide therapy pi...

Jun 5, 2023